Oak Ridge, TN – October 13, 2023 — Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today announces that experts recommend the use of blood volume analysis (BVA) to guide optimal treatment in heart failure patient at two Scientific Sessions held during the Heart Failure Society of America Annual Scientific Meeting on October 8th & 9th, 2023, at the Huntington Convention Center in Cleveland, OH.

Highlights from the sessions included:

• Expert panelists from Duke Clinical Health, the Mayo Clinic, and Wellstar presented case studies and peer-reviewed data showing BVA to be an essential diagnostic tool for their practice
• BVA was identified as a unique tool to determine intravascular volume profiles, guiding the most appropriate individualized patient management Implementing BVA led to improved patient outcomes, decreases in hospital length of stay, and provided positive return on investment for panelists sharing their clinical experience
• Daxor’s technology was also featured in an expert panel on Innovative Devices for Heart Failure Management highlighting the added benefit that it is now available and cleared for use by FDA

Historically, clinicians have made care decisions based on proxy pressure-based hemodynamics assessments, but data show pressure is often a poor proxy for volume, and optimal volume care is the cornerstone of effective heart failure congestion care. The first session, titled, “Managing Congestion: Targeting Pressure vs. Volume,” was co-moderated by Dr. Arvind Bhimaraj, Houston Methodist DeBakey Heart and Vascular and Dr. Marat Fudim, Duke University Health. Panel members including Dr. Wayne Miller, Mayo Clinic, Dr. Brian Howard, Wellstar, and Stephanie Barnes, CHFN, Duke University Hospital all called for the routine use of BVA to improve heart failure care. 

Dr. Miller stated, “If you don’t measure, you don’t know volume.”  Dr. Miller also highlighted the importance of knowing the red blood cell volume to optimize fluid management which is a key metric of Daxor’s BVA diagnostic blood test.